Lidocaine/tetracaine topical patch - Crescita Therapeutics

Drug Profile

Lidocaine/tetracaine topical patch - Crescita Therapeutics

Alternative Names: Enhanced Formulation - Crescita Therapeutics; Heated lidocaine/tetracaine patch; Heated tetracaine/lidocaine topical patch; HLT Patch; Ralydan; Rapydan; S-Caine™ Patch; Synera

Latest Information Update: 03 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ZARS
  • Developer Nuvo Research
  • Class Acetanilides; Aminobenzoic acids; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Procedural pain
  • Phase II Musculoskeletal pain

Most Recent Events

  • 25 Apr 2017 Lidocaine/tetracaine topical patch licensed to Taro Pharmaceuticals Inc in USA
  • 25 Apr 2017 Crescita Therapeutics has patents pending for lidocaine/tetracaine topical patch (Enhanced Formulation) in USA
  • 01 Apr 2015 The product is still in phase-II development for Musculoskeletal pain in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top